Ranbaxy’s Ongoing Issues With FDA Continue Novartis Windfall With Diovan
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the U.S., further delaying approval of generic valsartan. Novartis has recently revised its sales guidance due to lower than expected generic sales erosion in the U.S. this year.
You may also be interested in...
Ranbaxy Excludes One-off Gains In Altered Sales Guidance, As Guessing Game Continues On Valsartan
The Indian drug maker came out with subdued third quarter numbers in the face of adverse conditions in its home market. However, Ranbaxy keeps its hopes pinned on potential upsides in the U.S. from products like valsartan.
Ranbaxy Excludes One-off Gains In Altered Sales Guidance As Guessing Game Continues On Valsartan
The Indian drug maker came out with subdued third quarter numbers in the face of adverse conditions in its home market. However, Ranbaxy has kept its hopes pinned on potential upsides in the U.S. from products like valsartan.
Novartis’ Reprieve On Generic Diovan Continues, Tasigna Makes Inroads
The Swiss drug maker’s executives wouldn’t discuss overall progress of its strategic review under new chairman Joerg Reinhardt on its third quarter conference call, but highlighted the growth of several of its key pharmaceutical products and raised its outlook for 2013 in light of Diovan’s strength.